Sulbactam: a beta-lactamase inhibitor.

Area of Science:

• Pharmacology
• Microbiology
• Clinical Medicine

Background:

• Sulbactam is a beta-lactamase inhibitor that restores the efficacy of beta-lactam antibiotics.
• It exhibits weak intrinsic antibacterial activity but synergizes with beta-lactam antibiotics, particularly against beta-lactamase-producing bacteria.
• Available as sulbactam sodium with ampicillin sodium, and as oral sultamicillin (in clinical trials).

Purpose of the Study:

• To review the chemistry, pharmacology, microbiology, pharmacokinetics, clinical efficacy, and adverse effects of sulbactam.
• To evaluate the clinical utility of sulbactam in combination with ampicillin.
• To assess the safety and effectiveness of sulbactam-ampicillin for treating bacterial infections.

Main Methods:

• Review of existing literature on sulbactam's properties and clinical applications.
• Analysis of pharmacokinetic data for ampicillin and sulbactam.
• Evaluation of clinical trial data and reported outcomes for sulbactam-ampicillin therapy.

Main Results:

• Sulbactam-ampicillin is effective against polymicrobial aerobic/anaerobic infections and uncomplicated gonorrhea.
• The combination is not effective against Pseudomonas infections.
• Reported adverse effects include persistence, relapse, and superinfections in some cases, but the combination is generally well tolerated.

Conclusions:

• Sulbactam offers a valuable approach to managing bacterial infections by enhancing established beta-lactam antibiotics.
• The sulbactam-ampicillin combination is a safe and appealing option for treating gram-negative nonpseudomonal and anaerobic infections.
• Further investigation into sultamicillin, an oral prodrug, is ongoing.